|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GUCY1B1 |
Gene summary for GUCY1B1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GUCY1B1 | Gene ID | 2983 |
| Gene name | guanylate cyclase 1 soluble subunit beta 1 | |
| Gene Alias | GC-S-beta-1 | |
| Cytomap | 4q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q02153 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2983 | GUCY1B1 | S027 | Human | Liver | HCC | 2.14e-11 | 6.95e-01 | 0.2446 |
| 2983 | GUCY1B1 | S028 | Human | Liver | HCC | 1.99e-26 | 6.99e-01 | 0.2503 |
| 2983 | GUCY1B1 | S029 | Human | Liver | HCC | 1.87e-16 | 4.13e-01 | 0.2581 |
| 2983 | GUCY1B1 | male-WTA | Human | Thyroid | PTC | 2.43e-03 | 8.42e-02 | 0.1037 |
| 2983 | GUCY1B1 | PTC06 | Human | Thyroid | PTC | 1.97e-05 | 1.74e-01 | 0.2057 |
| 2983 | GUCY1B1 | ATC13 | Human | Thyroid | ATC | 2.82e-21 | 5.12e-01 | 0.34 |
| 2983 | GUCY1B1 | ATC5 | Human | Thyroid | ATC | 4.60e-30 | 5.89e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
| GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
| GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
| GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
| GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
| GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
| GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
| GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
| GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
| GO:004639012 | Liver | HCC | ribose phosphate biosynthetic process | 116/7958 | 190/18723 | 1.79e-07 | 3.29e-06 | 116 |
| GO:000926012 | Liver | HCC | ribonucleotide biosynthetic process | 111/7958 | 182/18723 | 3.53e-07 | 6.03e-06 | 111 |
| GO:000915212 | Liver | HCC | purine ribonucleotide biosynthetic process | 101/7958 | 169/18723 | 4.30e-06 | 5.50e-05 | 101 |
| GO:007252212 | Liver | HCC | purine-containing compound biosynthetic process | 114/7958 | 200/18723 | 2.36e-05 | 2.49e-04 | 114 |
| GO:000616412 | Liver | HCC | purine nucleotide biosynthetic process | 107/7958 | 191/18723 | 1.08e-04 | 9.22e-04 | 107 |
| GO:007124112 | Liver | HCC | cellular response to inorganic substance | 119/7958 | 226/18723 | 1.26e-03 | 6.92e-03 | 119 |
| GO:190217011 | Liver | HCC | cellular response to reactive nitrogen species | 13/7958 | 18/18723 | 1.05e-02 | 3.89e-02 | 13 |
| GO:001969327 | Thyroid | PTC | ribose phosphate metabolic process | 176/5968 | 396/18723 | 8.28e-08 | 1.70e-06 | 176 |
| GO:000915028 | Thyroid | PTC | purine ribonucleotide metabolic process | 165/5968 | 368/18723 | 1.03e-07 | 2.05e-06 | 165 |
| GO:007252127 | Thyroid | PTC | purine-containing compound metabolic process | 182/5968 | 416/18723 | 1.92e-07 | 3.51e-06 | 182 |
| GO:000925927 | Thyroid | PTC | ribonucleotide metabolic process | 170/5968 | 385/18723 | 2.32e-07 | 4.08e-06 | 170 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2983 | GUCY1B1 | DRUGGABLE GENOME | positive modulator | CHEMBL2107834 | RIOCIGUAT | |
| 2983 | GUCY1B1 | DRUGGABLE GENOME | activator | CHEMBL136478 | SODIUM NITROPRUSSIDE | |
| 2983 | GUCY1B1 | DRUGGABLE GENOME | activator | CHEMBL1200689 | NITRIC OXIDE | |
| 2983 | GUCY1B1 | DRUGGABLE GENOME | RIOCIGUAT | RIOCIGUAT | ||
| 2983 | GUCY1B1 | DRUGGABLE GENOME | activator | CHEMBL6622 | ISOSORBIDE DINITRATE | |
| 2983 | GUCY1B1 | DRUGGABLE GENOME | Cinaciguat | CINACIGUAT | ||
| 2983 | GUCY1B1 | DRUGGABLE GENOME | activator | CHEMBL1311 | ISOSORBIDE MONONITRATE | |
| 2983 | GUCY1B1 | DRUGGABLE GENOME | Vericigiuat | |||
| 2983 | GUCY1B1 | DRUGGABLE GENOME | activator | CHEMBL730 | NITROGLYCERIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |